Quidel to Present Virtually at William Blair 40th Annual Growth Stock Conference
May 26 2020 - 4:10PM
Business Wire
Quidel Corporation (NASDAQ: QDEL), a provider of rapid
diagnostic testing solutions, cellular-based virology assays and
molecular diagnostic systems, announced today that it will present
at the William Blair 40th Annual Growth Stock Conference to be held
virtually on Wednesday, June 10, 2020.
Douglas Bryant, president and chief executive officer, and Randy
Steward, chief financial officer, will present on that day at 10:40
a.m. Central time (8:40 a.m. Pacific time) in a question-and-answer
teleconference format. During the presentation, the company will
discuss business and financial developments and trends. The
company's statements may contain or constitute material information
that has not been previously disclosed.
A live webcast and audio archive of the presentation will be
available via the Investor Relations section of the company’s
website at http://ir.quidel.com or by clicking the link below:
http://www.wsw.com/webcast/blair56/qdel
Participants should allow approximately five to ten minutes
prior to the presentation's start time to visit the site and
download any streaming media software needed to listen to the
Internet webcast. A replay of the webcast will also be available on
the company’s website for 14 days.
About Quidel Corporation
Quidel Corporation serves to enhance the health and well-being
of people around the globe through the development of diagnostic
solutions that can lead to improved patient outcomes and provide
economic benefits to the healthcare system. Marketed under the
Sofia®, QuickVue®, D3® Direct Detection, Thyretain®, Triage® and
InflammaDry® leading brand names, as well as under the new Solana®,
AmpliVue® and Lyra® molecular diagnostic brands, Quidel’s products
aid in the detection and diagnosis of many critical diseases and
conditions, including, among others, influenza, respiratory
syncytial virus, Strep A, herpes, pregnancy, thyroid disease and
fecal occult blood. Quidel's Triage® system of tests comprises a
comprehensive test menu that provides rapid, cost-effective
treatment decisions at the point-of-care (POC), offering a diverse
immunoassay menu in a variety of tests to provide diagnostic
answers for quantitative BNP, CK-MB, d-dimer, myoglobin, troponin I
and qualitative TOX Drug Screen. Quidel’s research and development
engine is also developing a continuum of diagnostic solutions from
advanced immunoassay to molecular diagnostic tests to further
improve the quality of healthcare in physicians’ offices and
hospital and reference laboratories. For more information about
Quidel’s comprehensive product portfolio, visit quidel.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200526005787/en/
Quidel Contact: Quidel Corporation Randy Steward Chief Financial
Officer (858) 552-7931
Media and Investors Contact: Quidel Corporation Ruben Argueta
(858) 646-8023 rargueta@quidel.com
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Apr 2023 to Apr 2024